Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq: SIAL), announced the expansion of its CompoZr® Oncology Disease Model portfolio with the release of the first in its collection of breast cancer-specific knockout and knockin cell lines for drug discovery and research. These modified epithelial cell lines are expected to provide researchers with a characterized and known genetic background for basic research and pathway analysis...
More...
More...